Sebelipase alfa over 52 weeks reduces serum transaminases, liver volume and improves serum lipids in patients with lysosomal acid lipase deficiency.

MLA

Valayannopoulos, Vassili, et al. “Sebelipase Alfa over 52 Weeks Reduces Serum Transaminases, Liver Volume and Improves Serum Lipids in Patients with Lysosomal Acid Lipase Deficiency.” Journal of Hepatology, vol. 61, no. 5, Nov. 2014, pp. 1135–42. EBSCOhost, https://doi.org/10.1016/j.jhep.2014.06.022.

APA

Valayannopoulos, V., Malinova, V., Honzík, T., Balwani, M., Breen, C., Deegan, P. B., Enns, G. M., Jones, S. A., Kane, J. P., Stock, E. O., Tripuraneni, R., Eckert, S., Schneider, E., Hamilton, G., Middleton, M. S., Sirlin, C., Kessler, B., Bourdon, C., Boyadjiev, S. A., … Quinn, A. G. (2014). Sebelipase alfa over 52 weeks reduces serum transaminases, liver volume and improves serum lipids in patients with lysosomal acid lipase deficiency. Journal of Hepatology, 61(5), 1135–1142. https://doi.org/10.1016/j.jhep.2014.06.022

Chicago

Valayannopoulos, Vassili, Vera Malinova, Tomas Honzík, Manisha Balwani, Catherine Breen, Patrick B Deegan, Gregory M Enns, et al. 2014. “Sebelipase Alfa over 52 Weeks Reduces Serum Transaminases, Liver Volume and Improves Serum Lipids in Patients with Lysosomal Acid Lipase Deficiency.” Journal of Hepatology 61 (5): 1135–42. doi:10.1016/j.jhep.2014.06.022.